Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies (IMABs) for the treatment…
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies (IMABs) for the treatment…
Ganymed Pharmaceuticals AG announced today that its Ideal Monoclonal Antibody IMAB362 demonstrated significant safety an…
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly selective Ideal Monoclonal Antibodies (IMABs)…
Ganymed Pharmaceuticals AG announced today that the Food and Drug Administration (FDA) and the European Medicines Agency…
Ganymed Pharmaceuticals announced today that it has fully developed and obtained CE marking for its in vitro diagnostic…
GANYMED Pharmaceuticals AG today announced the closing of a EUR 65 M financing round. The round was led by ATS Beteiligu…
GANYMED Pharmaceuticals AG today announced the sale of a majority of the company shares to ATS. The shares that have bee…
GANYMED Pharmaceuticals AG gab heute den Verkauf einer Aktienmehrheit an die ATS bekannt. Ingro Finanz, KfW, Landesbank…